C
HLB바이오스텝
278650KOSDAQ자연과학 및 공학 연구개발업52.5 / 100
Reference Date: 2026-04-13
Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Rose 5.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
HLB Biosstep specializes in non-clinical CRO services, particularly in efficacy evaluation for pharmaceutical development, leveraging its expertise in high-complexity experiments using major animals like pigs and beagles. The company expanded its offerings in 2024 by acquiring HLB BioCode, a GLP toxicity testing specialist, and also provides animal facility construction and maintenance services.
Number of Employees
150people
Average Salary
61.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
1.11Industry Average 3.827.0Point
Half of industry avg (excellent)
ROE
-18.60Industry Average -32.113.5Point
Below industry avg
Debt Ratio
6.60Industry Average 7.524.0Point
In line with industry avg
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲18.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼441.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (32%)
Current 1,288Won52-week high 1,68352-week low 1,099
1-month return4.0Point
1m +5.40% (slight rise)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral정기주주총회결과2026-03-26
- Neutral기업설명회(IR)개최2026-03-25
- Neutral기업설명회(IR)개최2026-03-25
- Neutral[첨부정정]사업보고서 (2025.12)2026-03-23
- Neutral감사보고서제출2026-03-18